[131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumo

Dosimetry and therapeutic application of [131I]-Tyr3-octreotide were evaluated in three patients with metastatic paraganglioma and carcinoid tumor. The in vitro stability of [131I]Tyr3-octreotide was verified. Tumor uptake and residence time were between 0.02 and 0.1% and 0.5 to 9.8 h, respectively. The calculated tumor radiation doses were between 0.105 and 0.696 mGy·MBq-1. No intolerance or adverse effects were observed after the therapeutic doses (3.3¯6.6 GBq). A partial tumor response was obtained in one patient and no response occurred in two patients.